Aifei Pharma, an AI-centric drug research and development enterprise, has recently declared the triumphant conclusion of its angel round financing, amassing tens of millions of yuan. This financing round was spearheaded by Xianghe Capital, with contributions from Starlink Capital, a fund under Zhipu AI, alongside a renowned industrial fund. The capital raised will be predominantly allocated to the research and development of foundational drug models and AI-driven drug R&D agent engines, establishing a dry-wet closed-loop system for multimodal drug R&D, and expediting the progress of innovative drug pipelines. Presently, its most advanced pipeline has reached the Pre-PCC (Preclinical Candidate Compound) stage.

The cornerstone technology of Aifei Pharma hails from the team at the Institute for AI Industry Research (AIR) at Tsinghua University, concentrating on three pivotal capabilities: exploration, decision-making, and evolution. The company leverages the DrugCLIP foundational drug model to expand the chemical space, employs AI drug R&D agents, PharmAgents, to make intricate R&D decisions, and fosters continuous learning and evolution within the system.

Aifei Pharma seamlessly integrates AI technology into real-world R&D scenarios, with a steadfast commitment to developing autonomous First-in-Class (FIC) pipelines, striving to construct an AI Agent-driven 'virtual pharmaceutical enterprise.' Its business model revolves around collaborative development, and it has forged partnerships with numerous pharmaceutical companies, Biotech firms, top-tier research institutions, and hospitals to ensure close alignment with clinical needs.